forme_membres_ICBMS Dr Laurent ETTOUATI


Associate professor

Download Resume

About Laurent

Trained as a pharmacist, I specialized in organic chemistry, more particularly in structural determination and semisynthesis from natural compounds. Following my recruitment as a lecturer, I then participated in projects in biological fields using peptide synthesis and conventional organic chemistry techniques. I have also been interested more recently in the study of the stability of active ingredients.

Research interests

Currently, I participate in medicinal chemistry research projects in the field of cancerology, with the design of small molecules aimed at inhibiting Casein Kinase 2.

Selected publications

- QSAR Model of Indeno[1,2-b]indole Derivatives and Identification of N-isopentyl-2-methyl-4,9-dioxo-4,9-Dihydronaphtho[2,3-b]furan-3-carboxamide as a Potent CK2 Inhibitor.

Haidar, S.; Marminon, C.; Aichele, D.; Nacereddine, A.; Zeinyeh, W.; Bouzina, A.; Berredjem M.; Ettouati, L.; Bouaziz, Z.; Le Borgne, M.; Jose, J. Molecules 2020, 25, 97.

- Behaviour of Tetrabenazine in Acid Medium: Reassessment and Impact on Formulation.

Ettouati, L.; Senta-Loys, Z.; Bourgeois, S.; Fenet, B.; Le Borgne, M.; Fessi, H. Pharmaceutics 2019, 11, 44.


- Structure-based design and profiling of novel 17β-HSD14 inhibitors.

Braun, F.; Bertoletti, N.; Möller, G.; Adamski, J.; Frotscher, M.; Guragossian, N.; Alexandra Madeira Gírio, P; Le Borgne, M.; Ettouati, L.; Falson, P.; Müller, S.; Vollmer, G.; Heine, A.; Klebe, G.; Marchais-Oberwinkler, S. Eur. J. Med. Chem. 2018, 155, 61-76.

Publications Find the most recent scientific contributions

4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects

Robin Birus, Ehab El-Awaad, Laurens Ballentin, Faten Alchab, Dagmar Aichele, Laurent Ettouati, Claudia Götz, Marc Le Borgne, Joachim Jose*

FEBS Open Bio 2022, 12, 394–411

Read the whole publication

Contact us We are open to any
new scientific partnership!

Contact us